Case Report
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Mar 6, 2024; 12(7): 1296-1304
Published online Mar 6, 2024. doi: 10.12998/wjcc.v12.i7.1296
Extended survival with metastatic pancreatic cancer under fruquintinib treatment after failed chemotherapy: Two case reports
Dan Wu, Qiong Wang, Shuai Yan, Xia Sun, Ya Qin, Ming Yuan, Nan-Yao Wang, Xian-Ting Huang
Dan Wu, Qiong Wang, Shuai Yan, Xia Sun, Ya Qin, Ming Yuan, Nan-Yao Wang, Xian-Ting Huang, Department of Oncology, Jiangyin People's Hospital, Wuxi 214400, Jiangsu Province, China
Co-first authors: Dan Wu and Shuai Yan.
Author contributions: Wu D and Yan S contributed equally to this work in managing cases and recorded; Wang Q reviewed the manuscript; All authors have read and approved the final manuscript.
Supported by Found by the General Program of Wuxi Health and Health Committee, No. MS201908.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: All the authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qiong Wang, MD, Chief Doctor, Professor, Department of Oncology, Jiangyin People's Hospital, No. 163 Shoushan Road, Jiangyin City, Jiangsu Province, China. wangqiong55@hotmail.com
Received: October 8, 2023
Peer-review started: October 8, 2023
First decision: December 1, 2023
Revised: January 2, 2024
Accepted: February 5, 2024
Article in press: February 5, 2024
Published online: March 6, 2024
Processing time: 145 Days and 0.8 Hours
Core Tip

Core Tip: These two cases achieved a progress-free survival benefit from later-line single-agent fruquintinib therapy. With its better safety profile, fruquintinib may be worth exploring and studying in more depth as a later-line treatment for pancreatic cancer patients. This is the first literary report on Fruquintinib used in metastasis pancreatic cancers.